Susquehanna International Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.2M | Sell |
145,400
-77,000
| -35% | -$10.2M | ﹤0.01% | 2274 |
|
|
2025
Q4 | $31.5M | Buy |
222,400
+50,100
| +29% | +$7.26M | ﹤0.01% | 1770 |
|
|
2025
Q3 | $24.2M | Buy |
172,300
+93,200
| +118% | +$12.6M | ﹤0.01% | 2004 |
|
|
2025
Q2 | $9.94M | Sell |
79,100
-82,300
| -51% | -$9.44M | ﹤0.01% | 2841 |
|
|
2025
Q1 | $17.9M | Buy |
161,400
+137,700
| +581% | +$17.4M | ﹤0.01% | 1848 |
|
|
2024
Q4 | $3.24M | Sell |
23,700
-134,700
| -85% | -$16.7M | ﹤0.01% | 4337 |
|
|
2024
Q3 | $18.3M | Buy |
158,400
+79,200
| +100% | +$10.9M | ﹤0.01% | 1920 |
|
|
2024
Q2 | $10.9M | Sell |
79,200
-30,600
| -28% | -$4.2M | ﹤0.01% | 2376 |
|
|
2024
Q1 | $15.1M | Buy |
109,800
+15,100
| +16% | +$2.06M | ﹤0.01% | 2095 |
|
|
2023
Q4 | $12.5M | Buy |
94,700
+1,900
| +2% | +$219K | ﹤0.01% | 2353 |
|
|
2023
Q3 | $10.4M | Buy |
92,800
+60,200
| +185% | +$6.34M | ﹤0.01% | 2512 |
|
|
2023
Q2 | $3.07M | Sell |
32,600
-52,400
| -62% | -$5.12M | ﹤0.01% | 4327 |
|
|
2023
Q1 | $8.6M | Buy |
85,000
+79,500
| +1,445% | +$8.27M | ﹤0.01% | 2662 |
|
|
2022
Q4 | $657K | Sell |
5,500
-12,000
| -69% | -$1.41M | ﹤0.01% | 7169 |
|
|
2022
Q3 | $1.86M | Buy |
17,500
+2,900
| +20% | +$294K | ﹤0.01% | 5062 |
|
|
2022
Q2 | $1.42M | Sell |
14,600
-55,500
| -79% | -$5.12M | ﹤0.01% | 5679 |
|
|
2022
Q1 | $6.57M | Buy |
70,100
+12,200
| +21% | +$1.03M | ﹤0.01% | 3191 |
|
|
2021
Q4 | $4.93M | Buy |
57,900
+27,500
| +90% | +$2.53M | ﹤0.01% | 3765 |
|
|
2021
Q3 | $2.92M | Sell |
30,400
-27,700
| -48% | -$2.62M | ﹤0.01% | 5017 |
|
|
2021
Q2 | $5.65M | Sell |
58,100
-1,100
| -2% | -$105K | ﹤0.01% | 3820 |
|
|
2021
Q1 | $5.76M | Sell |
59,200
-83,200
| -58% | -$8.72M | ﹤0.01% | 3639 |
|
|
2020
Q4 | $13.6M | Sell |
142,400
-17,400
| -11% | -$1.68M | ﹤0.01% | 2132 |
|
|
2020
Q3 | $15.4M | Buy |
159,800
+24,000
| +18% | +$2.78M | ﹤0.01% | 1751 |
|
|
2020
Q2 | $16.6M | Buy |
135,800
+44,700
| +49% | +$4.94M | ﹤0.01% | 1602 |
|
|
2020
Q1 | $7.88M | Buy |
91,100
+8,400
| +10% | +$822K | ﹤0.01% | 2029 |
|
|
2019
Q4 | $8.89M | Sell |
82,700
-72,200
| -47% | -$7.56M | ﹤0.01% | 2213 |
|
|
2019
Q3 | $14M | Buy |
154,900
+34,000
| +28% | +$3.18M | ﹤0.01% | 1643 |
|
|
2019
Q2 | $10.2M | Sell |
120,900
-12,600
| -9% | -$1.03M | ﹤0.01% | 1859 |
|
|
2019
Q1 | $11.8M | Sell |
133,500
-7,600
| -5% | -$635K | ﹤0.01% | 1591 |
|
|
2018
Q4 | $10.1M | Sell |
141,100
-52,200
| -27% | -$5M | ﹤0.01% | 1604 |
|
|
2018
Q3 | $23.8M | Sell |
193,300
-2,500
| -1% | -$284K | 0.01% | 1196 |
|
|
2018
Q2 | $19.2M | Buy |
195,800
+85,900
| +78% | +$7.69M | 0.01% | 1335 |
|
|
2018
Q1 | $9.11M | Sell |
109,900
-53,500
| -33% | -$4.52M | ﹤0.01% | 1871 |
|
|
2017
Q4 | $12.7M | Buy |
163,400
+6,600
| +4% | +$450K | ﹤0.01% | 1630 |
|
|
2017
Q3 | $9.61M | Sell |
156,800
-7,400
| -5% | -$390K | ﹤0.01% | 1804 |
|
|
2017
Q2 | $7.55M | Sell |
164,200
-22,800
| -12% | -$1.11M | ﹤0.01% | 1945 |
|
|
2017
Q1 | $8.1M | Buy |
187,000
+71,900
| +62% | +$3.08M | ﹤0.01% | 1838 |
|
|
2016
Q4 | $4.45M | Buy |
115,100
+49,400
| +75% | +$2.24M | ﹤0.01% | 2605 |
|
|
2016
Q3 | $3.33M | Sell |
65,700
-89,700
| -58% | -$4.47M | ﹤0.01% | 2750 |
|
|
2016
Q2 | $7.06M | Sell |
155,400
-33,600
| -18% | -$1.55M | ﹤0.01% | 1792 |
|
|
2016
Q1 | $7.47M | Buy |
189,000
+60,000
| +47% | +$2.38M | ﹤0.01% | 1825 |
|
|
2015
Q4 | $7.3M | Sell |
129,000
-79,000
| -38% | -$4.02M | ﹤0.01% | 2081 |
|
|
2015
Q3 | $8.28M | Buy |
208,000
+114,400
| +122% | +$5.53M | ﹤0.01% | 2050 |
|
|
2015
Q2 | $4.47M | Buy |
93,600
+41,900
| +81% | +$1.78M | ﹤0.01% | 3096 |
|
|
2015
Q1 | $2.05M | Sell |
51,700
-80,400
| -61% | -$2.88M | ﹤0.01% | 4279 |
|
|
2014
Q4 | $2.95M | Sell |
132,100
-81,300
| -38% | -$1.54M | ﹤0.01% | 3767 |
|
|
2014
Q3 | $3.34M | Buy |
213,400
+8,100
| +4% | +$121K | ﹤0.01% | 3705 |
|
|
2014
Q2 | $3.05M | Buy |
205,300
+31,300
| +18% | +$442K | ﹤0.01% | 3897 |
|
|
2014
Q1 | $2.8M | Buy |
174,000
+99,300
| +133% | +$1.7M | ﹤0.01% | 3760 |
|
|
2013
Q4 | $698K | Sell |
74,700
-148,000
| -66% | -$1.44M | ﹤0.01% | 6148 |
|
|
2013
Q3 | $2.52M | Buy |
222,700
+30,300
| +16% | +$417K | ﹤0.01% | 3749 |
|
|
2013
Q2 | $2.57M | Buy |
+192,400
| New | +$2.36M | ﹤0.01% | 3509 |
|
Other funds holding NBIX
VPM
VCM
Susquehanna International Group's NBIX Position: Q1 2026 in Review
Susquehanna International Group reduced its Neurocrine Biosciences (NBIX) stake by 10% in Q1 2026, selling an estimated $1.32M and leaving 87,727 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2898.
Susquehanna International Group first reported a position in NBIX in Q2 2013 and has held it in 45 quarters since. The position peaked at $20.7M in Q3 2020. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Susquehanna International Group held 87,727 shares of Neurocrine Biosciences worth $11.6M as of Q1 2026.
- Susquehanna International Group sold 9,986 Neurocrine Biosciences shares in Q1 2026, an estimated $1.32M.
- Neurocrine Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2898 holding.
- Susquehanna International Group first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 45 quarters since.
- Susquehanna International Group's Neurocrine Biosciences position peaked at $20.7M in Q3 2020.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.